NYSE:NVO - Novo Nordisk A/S Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$47.73 -0.37 (-0.77 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$47.73
Today's Range$47.6050 - $47.99
52-Week Range$41.03 - $58.37
Volume704,460 shs
Average Volume1.37 million shs
Market Capitalization$117.53 billion
P/E Ratio20.40
Dividend Yield1.90%
Beta0.66

About Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S logoNovo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity. The Biopharmaceuticals segment offers products in the areas of haemophilia care, growth hormone therapy, and hormone replacement therapy. Novo Nordisk A/S has a research and licensing agreement with DUKE National University Singapore Medical School to develop stem cell-based treatments for chronic heart failure and age-related macular degeneration. The company markets and distributes its products through distributors and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:NVO
CUSIPN/A
Phone45-4444-8888

Debt

Debt-to-Equity RatioN/A
Current Ratio1.13
Quick Ratio0.77

Price-To-Earnings

Trailing P/E Ratio20.40
Forward P/E Ratio18.22
P/E Growth2.48

Sales & Book Value

Annual Sales$16.96 billion
Price / Sales6.88
Cash Flow$2.5470 per share
Price / Cash18.74
Book Value$2.99 per share
Price / Book15.96

Profitability

EPS (Most Recent Fiscal Year)$2.34
Net Income$5.79 billion
Net Margins35.21%
Return on Equity82.78%
Return on Assets40.01%

Miscellaneous

Employees42,076
Outstanding Shares2,443,530,000

Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a special dividend on Monday, February 5th. Stockholders of record on Monday, March 26th will be given a dividend of $0.8117 per share on Tuesday, April 3rd. This represents a dividend yield of 0.96%. The ex-dividend date of this dividend is Friday, March 23rd. View Novo Nordisk A/S's Dividend History.

How will Novo Nordisk A/S's stock buyback program work?

Novo Nordisk A/S declared that its board has authorized a stock buyback program on Friday, February 2nd 2018, which authorizes the company to repurchase shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's leadership believes its shares are undervalued.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings data on Friday, April, 29th. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.53 by $0.02. The company earned $4.02 billion during the quarter, compared to the consensus estimate of $4.07 billion. Novo Nordisk A/S had a return on equity of 82.78% and a net margin of 35.21%. View Novo Nordisk A/S's Earnings History.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Novo Nordisk A/S.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a increase in short interest in the month of April. As of April 30th, there was short interest totalling 2,147,542 shares, an increase of 53.4% from the April 13th total of 1,399,529 shares. Based on an average trading volume of 1,608,993 shares, the days-to-cover ratio is presently 1.3 days.

Who are some of Novo Nordisk A/S's key competitors?

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the folowing people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 52)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 58)
  • Mr. Jesper Brandgaard, Exec. VP and Head of Biopharm & Legal Affairs (Age 55)
  • Ms. Liselotte Hyveled, Former Project VP for Faster-Acting Insulin Aspart & Prandial Bioedge Projects - Insulin & Director (Age 52)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 46)

Has Novo Nordisk A/S been receiving favorable news coverage?

Press coverage about NVO stock has trended somewhat negative recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novo Nordisk A/S earned a daily sentiment score of -0.02 on Accern's scale. They also gave headlines about the company an impact score of 45.85 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Loomis Sayles & Co. L P (0.90%), Fisher Asset Management LLC (0.54%), BlackRock Inc. (0.40%), Folketrygdfondet (0.23%), Fayez Sarofim & Co (0.19%) and Sustainable Growth Advisers LP (0.16%). View Institutional Ownership Trends for Novo Nordisk A/S.

Which institutional investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Folketrygdfondet, Envestnet Asset Management Inc., Millennium Management LLC, Wells Fargo & Company MN, UBS Group AG, Hutchinson Capital Management CA, Fayez Sarofim & Co and Reynders McVeigh Capital Management LLC. View Insider Buying and Selling for Novo Nordisk A/S.

Which institutional investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Fisher Asset Management LLC, Carillon Tower Advisers Inc., BlackRock Inc., Assetmark Inc., Sustainable Growth Advisers LP, Twin Tree Management LP and CIBC World Markets Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $47.73.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $117.53 billion and generates $16.96 billion in revenue each year. The company earns $5.79 billion in net income (profit) each year or $2.34 on an earnings per share basis. Novo Nordisk A/S employs 42,076 workers across the globe.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NVO)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  218 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  524
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Novo Nordisk A/S (NYSE:NVO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Novo Nordisk A/S in the last 12 months. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.602.602.331.86
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Novo Nordisk A/S (NYSE:NVO) Consensus Price Target History

Price Target History for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/8/2018Deutsche BankReiterated RatingBuyLowView Rating Details
12/29/2017JPMorgan Chase & Co.UpgradeUnderweight ➝ NeutralLowView Rating Details
12/6/2017Bank of AmericaUpgradeNeutral ➝ BuyMediumView Rating Details
12/1/2017Morgan StanleyUpgradeEqual Weight ➝ OverweightMediumView Rating Details
9/25/2017BNP ParibasDowngradeOutperform ➝ NeutralHighView Rating Details
3/7/2017BarclaysInitiated CoverageUnderweightN/AView Rating Details
12/20/2016Jefferies GroupReiterated RatingHoldN/AView Rating Details
12/6/2016UBSUpgradeSell ➝ BuyN/AView Rating Details
12/1/2016Credit Suisse GroupReiterated RatingHoldN/AView Rating Details
10/31/2016DNB MarketsDowngradeBuy ➝ HoldN/AView Rating Details
10/31/2016CitigroupDowngradeBuy ➝ NeutralN/AView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageNeutralN/AView Rating Details
9/13/2016Pacific CrestUpgradeNeutral ➝ OutperformN/AView Rating Details
6/28/2016Goldman Sachs GroupDowngradeConviction-Buy ➝ BuyN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Novo Nordisk A/S (NYSE:NVO) Earnings History and Estimates Chart

Earnings by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) Earnings Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.69$0.69$0.69

Novo Nordisk A/S (NYSE NVO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2018        
2/1/2018Q4 2017$0.57$0.53$4.2681 billion$4.4292 billionViewN/AView Earnings Details
11/1/2017Q3 2017$0.58$0.62$4.3007 billion$4.2033 billionViewN/AView Earnings Details
8/10/2017Q2 2017$0.56$0.59$4.2882 billion$4.2342 billionViewN/AView Earnings Details
5/3/2017Q1 2017$0.53$0.58$4.1122 billion$4.0774 billionViewN/AView Earnings Details
2/2/2017Q4 2016$0.52$0.50$4.3288 billion$4.29 billionViewN/AView Earnings Details
10/28/2016Q3 2016$0.56$0.58$4.2217 billion$4.1273 billionViewN/AView Earnings Details
8/5/2016Q2 2016$0.58$0.60$4.2092 billion$4.1688 billionViewN/AView Earnings Details
4/29/2016Q1$0.53$0.55$4.0676 billion$4.0232 billionViewListenView Earnings Details
2/3/2016Q4 2015$0.48$0.47$4.1561 billion$4.2390 billionViewN/AView Earnings Details
10/29/2015Q3$0.47$0.49$4.0256 billion$3.9947 billionViewN/AView Earnings Details
8/6/2015Q2 2015$0.48$3.9735 billion$4.0101 billionViewN/AView Earnings Details
4/30/2015Q1$0.39$0.45$25.1254 billion$25.20 billionViewN/AView Earnings Details
1/30/2015Q4$2.48$0.38$24.6673 billion$24.5850 billionViewN/AView Earnings Details
10/30/2014Q3 2014$0.42$3.8032 billionViewN/AView Earnings Details
8/7/2014Q2$2.60$0.48$21.8569 billion$21.6290 billionViewN/AView Earnings Details
5/1/2014Q1$0.44$0.45$20.8333 billion$20.30 billionViewN/AView Earnings Details
1/28/2014Q413$0.42$3.9710 billionViewN/AView Earnings Details
10/31/2013Q1$12.11$2.20$21.0426 billion$20.5110 billionViewN/AView Earnings Details
8/8/2013Q1$11.97$12.45$21.0879 billion$21.38 billionViewN/AView Earnings Details
5/1/2013$10.67$10.98$19.7317 billion$19.9830 billionViewN/AView Earnings Details
1/31/2013$9.77$10.53$20.8289 billion$20.9620 billionViewN/AView Earnings Details
10/31/2012Q312$9.43$10.33$57.10 millionViewN/AView Earnings Details
8/9/2012Q2 2012$0.32ViewN/AView Earnings Details
4/27/2012Q1 2012$0.30ViewN/AView Earnings Details
2/2/2012Q4 2011$0.26$0.30ViewN/AView Earnings Details
10/27/2011Q3 2011$0.27$0.28ViewN/AView Earnings Details
8/4/2011Q2 2011$0.29$0.28ViewN/AView Earnings Details
2/2/2011Q4 2010$0.27$0.25ViewN/AView Earnings Details
10/27/2010Q3 2010$0.23ViewN/AView Earnings Details
8/19/2010Q2 2010$0.19$0.21ViewN/AView Earnings Details
4/30/2010Q1 2009$0.16ViewN/AView Earnings Details
2/2/2010Q4 2009$0.16ViewN/AView Earnings Details
10/29/2009Q3 2009$0.18ViewN/AView Earnings Details
1/29/2009Q4 2008$0.13ViewN/AView Earnings Details
10/30/2008Q3 2008$0.17ViewN/AView Earnings Details
4/30/2008Q1 2008$0.14ViewN/AView Earnings Details
1/31/2008Q4 2007$0.06ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Novo Nordisk A/S (NYSE:NVO) Dividend Information

Novo Nordisk A/S pays an annual dividend of $0.91 per share, with a dividend yield of 1.91%. NVO's most recent special dividend payment was Tuesday, April 3. Novo Nordisk A/S pays out 38.89% of its earnings out as a dividend.
Most Recent Dividend:4/3/2018
Annual Dividend:$0.91
Dividend Yield:1.91%
Dividend Growth:10.40% (3 Year Average)
Payout Ratio(s):38.89% (Trailing 12 Months of Earnings)
34.73% (Based on This Year's Estimates)
33.96% (Based on Next Year's Estimates)
35.73% (Based on Cash Flow)
Dividend Payments by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/5/2018special$0.81170.96%3/23/20183/26/20184/3/2018
8/9/2017annual$0.33601.07%8/18/20178/21/20178/29/2017
2/7/2017annual$0.66341.99%3/23/20173/27/20174/4/2017
8/8/2016$0.32608/11/20168/15/20168/23/2016
2/16/2016Annual$0.70403/18/20163/22/20163/30/2016
3/17/2014annual$0.83901.83%3/21/20143/25/20144/2/2014
2/27/2013annual$3.18381.81%3/21/20133/25/20134/2/2013
(Data available from 1/1/2013 forward)

Insider Trades

Novo Nordisk A/S (NYSE NVO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.07%
Institutional Ownership Percentage: 6.70%
Insider Trading History for Novo Nordisk A/S (NYSE:NVO)
Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE NVO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/8/2017Eric S SprottInsiderBuy50,000$8.34$417,000.00
2/18/2015Richmond Partners Master LimitInsiderSell24,900$1.2802$31,876.98
(Data available from 1/1/2013 forward)

Headlines

Novo Nordisk A/S (NYSE NVO) News Headlines

Source:
DateHeadline
Almost a quarter of the world’s population will be obese by 2045Almost a quarter of the world’s population will be obese by 2045
finance.yahoo.com - May 24 at 8:48 AM
Eli Lillys Trulicity Benefits From Growth of Diabetes DrugsEli Lilly's Trulicity Benefits From Growth of Diabetes Drugs
finance.yahoo.com - May 23 at 5:09 PM
Short Interest in Novo Nordisk (NVO) Grows By 53.4%Short Interest in Novo Nordisk (NVO) Grows By 53.4%
www.americanbankingnews.com - May 16 at 3:14 AM
BioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical ConditionsBioLamina and Novo Nordisk Partner to Advance Stem Cell Based Therapies for Three Common Medical Conditions
www.prnewswire.com - May 16 at 2:42 AM
AstraZeneca’s 1Q18 Earnings: Analysts’ EstimatesAstraZeneca’s 1Q18 Earnings: Analysts’ Estimates
finance.yahoo.com - May 15 at 5:22 PM
Novo-Nordisk Breaks Above 200-Day Moving Average - Bullish for NVONovo-Nordisk Breaks Above 200-Day Moving Average - Bullish for NVO
www.nasdaq.com - May 14 at 4:59 PM
Novo Nordisk: Review Of Key Growth Drivers And Pipeline CandidatesNovo Nordisk: Review Of Key Growth Drivers And Pipeline Candidates
seekingalpha.com - May 10 at 8:58 AM
Novo Nordisk: An Objective AnalysisNovo Nordisk: An Objective Analysis
seekingalpha.com - May 8 at 5:05 PM
Emispheres Solid FutureEmisphere's Solid Future
seekingalpha.com - May 8 at 8:49 AM
Novo Nordisk: Q1 Earnings Results Show Bullish Thesis ContinuingNovo Nordisk: Q1 Earnings Results Show Bullish Thesis Continuing
seekingalpha.com - May 7 at 5:10 PM
Is Novo Nordisk A/S (NYSE:NVO) A Buy At Its Current PE Ratio?Is Novo Nordisk A/S (NYSE:NVO) A Buy At Its Current PE Ratio?
finance.yahoo.com - May 7 at 5:10 PM
Novo Nordisk Fights Payer Pressure With New MedsNovo Nordisk Fights Payer Pressure With New Meds
www.fool.com - May 7 at 4:32 PM
BRIEF-Novo Nordisk Says Initiated New Share Repurchase Programme For Up To Dkk 2.7 BillionBRIEF-Novo Nordisk Says Initiated New Share Repurchase Programme For Up To Dkk 2.7 Billion
www.reuters.com - May 5 at 9:01 AM
BRIEF-Novo Nordisk A/S purchases B Shares worth Dkk 1038 Mln from Novo Holdings A/S under 2018 share ...BRIEF-Novo Nordisk A/S purchases B Shares worth Dkk 1038 Mln from Novo Holdings A/S under 2018 share ...
www.reuters.com - May 5 at 9:01 AM
Novo Nordisk A/S - Share repurchase programmeNovo Nordisk A/S - Share repurchase programme
globenewswire.com - May 5 at 9:01 AM
Novo Nordisk (NVO) Q1 2018 Earnings Conference Call TranscriptNovo Nordisk (NVO) Q1 2018 Earnings Conference Call Transcript
finance.yahoo.com - May 3 at 4:56 PM
Novo Nordisk (NVO) Given Consensus Rating of "Hold" by BrokeragesNovo Nordisk (NVO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 3 at 11:16 AM
Novo Nordisk shares climb as it lifts sales and profitNovo Nordisk shares climb as it lifts sales and profit
www.ft.com - May 2 at 5:08 PM
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales MissNovo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss
www.zacks.com - May 2 at 5:08 PM
Novo Nordisk A/S (NVO) Q1 2018 Results - Earnings Call TranscriptNovo Nordisk A/S (NVO) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 5:08 PM
NVS and NVO: Which Has Higher Upside Potential?NVS and NVO: Which Has Higher Upside Potential?
finance.yahoo.com - May 2 at 5:08 PM
We have a policy of not taking list price increases of ab...We have a policy of not taking list price increases of ab...
finance.yahoo.com - May 2 at 8:50 AM
Drugmaker Novo Nordisk beats first quarter profit expectations, nudges up 2018 outlookDrugmaker Novo Nordisk beats first quarter profit expectations, nudges up 2018 outlook
finance.yahoo.com - May 2 at 8:50 AM
Novo Nordisk reports Q1 resultsNovo Nordisk reports Q1 results
seekingalpha.com - May 2 at 6:10 AM
Drugmaker Novo Nordisk beats first-quarter profit expectations, nudges up 2018 outlookDrugmaker Novo Nordisk beats first-quarter profit expectations, nudges up 2018 outlook
www.cnbc.com - May 2 at 5:34 AM
Is Novo Nordisk Undervalued Once Again?Is Novo Nordisk Undervalued Once Again?
seekingalpha.com - April 30 at 4:53 PM
GlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare BusinessGlaxoSmithKline’s 1Q18 Earnings: Consumer Healthcare Business
finance.yahoo.com - April 30 at 4:53 PM
Analyst Recommendations for Novo Nordisk in AprilAnalyst Recommendations for Novo Nordisk in April
finance.yahoo.com - April 27 at 9:13 AM
Emisphere Amends License Agreement with Novo NordiskEmisphere Amends License Agreement with Novo Nordisk
finance.yahoo.com - April 26 at 8:42 AM
Form 6-K NOVO NORDISK AS For: Apr 24Form 6-K NOVO NORDISK AS For: Apr 24
www.streetinsider.com - April 25 at 5:07 PM
Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)Dr. Philip Just Larsen Appointed Chief Scientific Officer (CSO)
www.prnewswire.com - April 23 at 4:52 PM
MannKind: Experts In Pulling Numbers From OrificesMannKind: Experts In Pulling Numbers From Orifices
seekingalpha.com - April 23 at 8:38 AM
Xultophy® approved in Canada for the treatment of adults with type 2 diabetesXultophy® approved in Canada for the treatment of adults with type 2 diabetes
finance.yahoo.com - April 18 at 5:16 PM
Novo Nordisk (NVO) Sees Large Decline in Short InterestNovo Nordisk (NVO) Sees Large Decline in Short Interest
www.americanbankingnews.com - April 18 at 2:16 AM
$0.69 Earnings Per Share Expected for Novo Nordisk (NVO) This Quarter$0.69 Earnings Per Share Expected for Novo Nordisk (NVO) This Quarter
www.americanbankingnews.com - April 16 at 3:24 AM
Equities Analysts Offer Predictions for Novo Nordisks Q1 2018 Earnings (NVO)Equities Analysts Offer Predictions for Novo Nordisk's Q1 2018 Earnings (NVO)
www.americanbankingnews.com - April 16 at 1:19 AM
Novo Nordisk (NVO) Stock Rating Lowered by BidaskClubNovo Nordisk (NVO) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 9:51 PM
Novo-Nordisk Breaks Below 200-Day Moving Average - Notable for NVONovo-Nordisk Breaks Below 200-Day Moving Average - Notable for NVO
www.nasdaq.com - April 13 at 5:04 PM
Novo Nordisk (NVO) Stock Rating Lowered by Zacks Investment ResearchNovo Nordisk (NVO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 12 at 12:33 PM
Tessa Therapeutics announces new Board Member and increase of recent funding roundTessa Therapeutics announces new Board Member and increase of recent funding round
www.prnewswire.com - April 11 at 7:28 PM
Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in CanadaNovo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada
finance.yahoo.com - April 11 at 9:17 AM
Novo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in QuebecNovo Nordisk announces the availability of Zonovate® for the treatment of patients with hemophilia A in Quebec
finance.yahoo.com - April 11 at 9:17 AM
Novo Nordisk Stock Performance in 1Q18Novo Nordisk Stock Performance in 1Q18
finance.yahoo.com - April 10 at 5:02 PM
Novo Nordisk (NVO) Given Average Rating of "Hold" by AnalystsNovo Nordisk (NVO) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 8 at 7:33 AM
Novo Nordisk (NVO) Upgraded by Zacks Investment Research to "Buy"Novo Nordisk (NVO) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 7 at 4:58 PM
Novo Nordisk Obtains Licence for Sickle Cell Disease ProgramNovo Nordisk Obtains Licence for Sickle Cell Disease Program
www.zacks.com - April 6 at 5:12 PM
Novo Nordisk buys blood drug licence to boost anaemic biopharma businessNovo Nordisk buys blood drug licence to boost anaemic biopharma business
finance.yahoo.com - April 5 at 10:54 AM
Status regarding Novo Nordisks holding of its own shares (31 March 2018)Status regarding Novo Nordisk's holding of its own shares (31 March 2018)
finance.yahoo.com - April 3 at 8:59 AM
Novo Nordisk (NVO) Earns Buy Rating from Deutsche BankNovo Nordisk (NVO) Earns Buy Rating from Deutsche Bank
www.americanbankingnews.com - March 30 at 12:34 PM
Novo Nordisk A/S (NVO) Downgraded by Zacks Investment ResearchNovo Nordisk A/S (NVO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 27 at 1:51 PM

SEC Filings

Novo Nordisk A/S (NYSE:NVO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Novo Nordisk A/S (NYSE:NVO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Novo Nordisk A/S (NYSE NVO) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.